Pomanda estimates the enterprise value of VIFOR PHARMA UK LIMITED at £46.5m based on a Turnover of £45.6m and 1.02x industry multiple (adjusted for size and gross margin).
vifor pharma uk limitedEstimated Valuation
£23.6m
Pomanda estimates the enterprise value of VIFOR PHARMA UK LIMITED at £23.6m based on an EBITDA of £2.5m and a 9.48x industry multiple (adjusted for size and gross margin).
vifor pharma uk limitedEstimated Valuation
£36.6m
Pomanda estimates the enterprise value of VIFOR PHARMA UK LIMITED at £36.6m based on Net Assets of £19.4m and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Vifor Pharma Uk LimitedOverview
Vifor Pharma Uk Limited is a live company located in london, EC4A 3TW with a Companies House number of 06514784. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in February 2008, it's largest shareholder is
vifor pharma participations ag
with a 100% stake. Vifor Pharma Uk Limited is a established,
large sized company, Pomanda has estimated its turnover at
£45.6m with
low
growth in recent years.
Pomanda's financial health check has awarded Vifor Pharma Uk Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
5 Strong
2 Regular
5 Weak
Size
annual sales of £45.6m, make it larger than the average company (£25.4m)
£45.6m - Vifor Pharma Uk Limited
£25.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 3%, show it is growing at a slower rate (5.5%)
3% - Vifor Pharma Uk Limited
5.5% - Industry AVG
Production
with a gross margin of 34.5%, this company has a lower cost of product (27.8%)
34.5% - Vifor Pharma Uk Limited
27.8% - Industry AVG
Profitability
an operating margin of 4.8% make it more profitable than the average company (4%)
4.8% - Vifor Pharma Uk Limited
4% - Industry AVG
Employees
with 69 employees, this is above the industry average (37)
69 - Vifor Pharma Uk Limited
37 - Industry AVG
Pay Structure
on an average salary of £168k, the company has a higher pay structure (£78.1k)
£168k - Vifor Pharma Uk Limited
£78.1k - Industry AVG
Efficiency
resulting in sales per employee of £660.3k, this is equally as efficient (£643.4k)
£660.3k - Vifor Pharma Uk Limited
£643.4k - Industry AVG
Debtor Days
it gets paid by customers after 95 days, this is later than average (57 days)
95 days - Vifor Pharma Uk Limited
57 days - Industry AVG
Creditor Days
its suppliers are paid after 12 days, this is quicker than average (29 days)
12 days - Vifor Pharma Uk Limited
29 days - Industry AVG
Stock Days
it holds stock equivalent to 139 days, this is more than average (62 days)
139 days - Vifor Pharma Uk Limited
62 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 32 weeks, this is more cash available to meet short term requirements (11 weeks)
32 weeks - Vifor Pharma Uk Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 52.3%, this is a similar level of debt than the average (52.4%)
52.3% - Vifor Pharma Uk Limited
52.4% - Industry AVG
VIFOR PHARMA UK LIMITED financials
EXPORT
Vifor Pharma Uk Limited's latest turnover from June 2024 is £45.6 million and the company has net assets of £19.4 million. According to their latest financial statements, Vifor Pharma Uk Limited has 69 employees and maintains cash reserves of £8.1 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Jun 2024
Jun 2023
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
45,561,121
66,664,495
41,168,184
36,468,572
43,346,556
35,620,520
31,325,766
24,008,807
26,714,494
27,525,806
23,141,991
22,817,623
13,482,139
9,498,009
8,737,529
Other Income Or Grants
Cost Of Sales
29,832,619
40,154,215
24,252,357
20,664,791
21,539,250
17,953,446
14,909,412
11,970,047
14,108,678
13,148,157
10,607,277
9,347,776
3,595,164
3,306,269
3,913,233
Gross Profit
15,728,502
26,510,280
16,915,827
15,803,781
21,807,306
17,667,074
16,416,354
12,038,760
12,605,816
14,377,649
12,534,714
13,469,847
9,886,975
6,191,740
4,824,296
Admin Expenses
13,546,349
23,735,780
15,591,163
14,286,284
20,483,606
16,727,750
15,517,966
11,362,129
12,477,464
13,679,256
12,128,110
12,794,858
31,214,599
6,159,077
4,666,388
Operating Profit
2,182,153
2,774,500
1,324,664
1,517,497
1,323,700
939,324
898,388
676,631
128,352
698,393
406,604
674,989
-21,327,624
32,663
157,908
Interest Payable
214,535
299,102
199,452
200,000
714,210
824,349
519,220
721,558
179,302
231,210
917
Interest Receivable
69
713
3,536,475
721,558
Pre-Tax Profit
1,967,687
2,476,111
1,125,212
1,317,497
1,323,700
939,324
898,388
676,631
24,035,987
-125,956
3,437,034
-46,569
-21,506,926
-198,547
156,991
Tax
-345,312
-637,804
-213,781
-211,034
-193,114
-155,638
-141,290
-137,716
130,786
-255,818
477,591
91,294
-43,763
Profit After Tax
1,622,375
1,838,307
911,431
1,106,463
1,130,586
783,686
757,098
538,915
24,166,773
-381,774
3,914,625
44,725
-21,506,926
-198,547
113,228
Dividends Paid
Retained Profit
1,622,375
1,838,307
911,431
1,106,463
1,130,586
783,686
757,098
538,915
24,166,773
-381,774
3,914,625
44,725
-21,506,926
-198,547
113,228
Employee Costs
11,593,455
15,703,965
9,759,422
10,005,416
10,589,584
8,900,515
7,620,218
6,610,204
6,571,817
7,296,789
5,796,004
5,415,870
4,548,063
2,110,124
Number Of Employees
69
63
83
109
106
94
76
69
101
109
99
91
52
42
EBITDA*
2,494,571
3,299,260
1,875,506
2,261,467
2,374,225
1,488,836
1,437,626
1,229,012
445,780
1,066,842
937,364
1,206,122
-20,818,128
539,284
157,908
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024
Jun 2023
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
478,392
1,810,075
2,304,867
2,834,620
3,296,199
227,466
211,127
186,788
201,835
1,877,651
2,110,118
5,791,978
6,108,362
3,626,806
Intangible Assets
4,535,353
4,535,353
4,535,353
4,535,353
4,547,854
5,054,365
5,571,543
6,087,054
6,602,695
12,465,156
13,133,561
13,812,928
14,490,599
9,177,839
4,535,353
Investments & Other
1,000
1,000
1,000
1,000
1,000
1,000
3,537,475
3,537,475
3,537,475
Debtors (Due After 1 year)
Total Fixed Assets
5,013,745
6,345,428
6,840,220
7,369,973
7,844,053
5,281,831
5,782,670
6,273,842
6,804,530
14,342,807
15,243,679
19,604,906
20,598,961
12,804,645
4,535,353
Stock & work in progress
11,421,364
17,485,244
14,202,645
17,139,688
19,705,442
279,642
54,811
2,186,633
2,068,012
1,636,581
1,622,196
268,341
387,678
Trade Debtors
11,959,906
12,586,299
9,913,937
8,044,169
8,477,991
6,156,917
6,694,515
5,068,941
4,496,723
4,882,118
4,542,965
4,189,842
3,297,383
1,023,250
1,088,378
Group Debtors
3,972,860
3,785,016
2,938,534
1,672,196
2,093,733
2,122,673
3,359,644
1,507,717
638,173
2,194,121
4,217,759
4,436,672
4,706,272
706,127
Misc Debtors
39,147
48,405
202,044
237,666
32,352
164,983
131,958
38,805
88,161
202,473
186,986
71,637
49,743
71,575
172,963
Cash
8,112,158
2,250,769
3,133,782
2,018,283
1,249,349
1,805,332
1,282,824
1,496,251
1,541,878
656,068
1,591,787
1,531,911
2,316,312
1,180,511
1,754,616
misc current assets
104,836
236
total current assets
35,610,271
36,155,733
30,390,942
29,112,002
31,558,867
10,529,783
11,468,941
8,111,714
6,819,746
10,121,413
12,607,509
11,866,643
11,991,906
3,249,804
3,403,635
total assets
40,624,016
42,501,161
37,231,162
36,481,975
39,402,920
15,811,614
17,251,611
14,385,556
13,624,276
24,464,220
27,851,188
31,471,549
32,590,867
16,054,449
7,938,988
Bank overdraft
Bank loan
96,527
88,062
122,340
79,723
Trade Creditors
985,693
814,726
576,181
311,538
291,896
350,642
343,706
338,830
224,403
601,062
520,984
654,686
1,413,785
438,310
818,247
Group/Directors Accounts
4,655,765
5,205,398
4,899,700
3,153,842
other short term finances
hp & lease commitments
65,724
230,960
260,570
518,645
364,153
other current liabilities
7,455,676
9,104,663
5,916,196
7,546,708
14,470,057
2,693,760
4,924,379
2,820,298
2,712,360
3,131,647
3,333,068
10,134,423
9,556,091
11,166,049
2,472,104
total current liabilities
13,162,858
15,355,747
11,652,647
11,530,733
15,126,106
3,044,402
5,268,085
3,159,128
2,936,763
3,829,236
3,942,114
10,911,449
11,049,599
11,604,359
3,290,351
loans
8,000,000
8,000,000
8,000,000
8,000,000
12,747,628
34,580,912
37,784,575
37,960,700
38,820,032
hp & lease commitments
1,306,631
1,657,621
1,941,779
2,373,814
Accruals and Deferred Income
other liabilities
provisions
79,582
79,582
512,200
82,558
1,037,734
1,518,682
total long term liabilities
8,079,582
9,386,213
9,657,621
9,941,779
10,373,814
34,114,244
37,006,560
37,572,211
38,598,104
total liabilities
21,242,440
24,741,960
21,310,268
21,472,512
25,499,920
3,044,402
5,268,085
3,159,128
2,936,763
37,943,480
40,948,674
48,483,660
49,647,703
11,604,359
3,290,351
net assets
19,381,576
17,759,201
15,920,894
15,009,463
13,903,000
12,767,212
11,983,526
11,226,428
10,687,513
-13,479,260
-13,097,486
-17,012,111
-17,056,836
4,450,090
4,648,637
total shareholders funds
19,381,576
17,759,201
15,920,894
15,009,463
13,903,000
12,767,212
11,983,526
11,226,428
10,687,513
-13,479,260
-13,097,486
-17,012,111
-17,056,836
4,450,090
4,648,637
Jun 2024
Jun 2023
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
2,182,153
2,774,500
1,324,664
1,517,497
1,323,700
939,324
898,388
676,631
128,352
698,393
406,604
674,989
-21,327,624
32,663
157,908
Depreciation
312,418
524,760
550,842
731,469
544,014
37,833
23,727
36,740
171,195
206,555
357,180
357,708
3,000
3,000
Amortisation
12,501
506,511
511,679
515,511
515,641
146,233
161,894
173,580
173,425
506,496
503,621
Tax
-345,312
-637,804
-213,781
-211,034
-193,114
-155,638
-141,290
-137,716
130,786
-255,818
477,591
91,294
-43,763
Stock
-6,063,880
17,485,244
-2,937,043
-2,565,754
19,425,800
279,642
-54,811
-2,131,822
118,621
431,431
14,385
1,353,855
-119,337
387,678
Debtors
-447,807
16,419,720
3,100,484
-650,045
2,159,503
-1,741,544
3,570,654
1,392,406
-2,055,655
-1,668,998
249,559
644,753
6,252,446
539,611
1,261,341
Creditors
170,967
814,726
264,643
19,642
-58,746
6,936
4,876
114,427
-376,659
80,078
-133,702
-759,099
975,475
-379,937
818,247
Accruals and Deferred Income
-1,648,987
9,104,663
-1,630,512
-6,923,349
11,776,297
-2,230,619
2,104,081
107,938
-419,287
-201,421
-6,801,355
578,332
-1,609,958
8,693,945
2,472,104
Deferred Taxes & Provisions
79,582
-512,200
429,642
-955,176
-480,948
1,518,682
Cash flow from operations
7,182,926
-21,244,537
132,415
-1,637,475
-7,686,641
571,417
-165,361
-23,934
3,455,897
2,669,700
-7,156,268
-23,437
-27,540,230
8,433,018
1,755,477
Investing Activities
capital expenditure
-3,612,747
-48,673
-48,066
-21,693
7,220,849
532,423
3,830,467
462,922
-8,303,812
-8,775,913
-4,535,353
Change in Investments
-1,000
-3,536,475
3,537,475
cash flow from investments
-3,611,747
-48,673
-48,066
-21,693
7,220,849
532,423
7,366,942
462,922
-8,303,812
-12,313,388
-4,535,353
Financing Activities
Bank loans
-96,527
8,465
-34,278
42,617
79,723
Group/Directors Accounts
-549,633
5,205,398
1,745,858
3,153,842
Other Short Term Loans
Long term loans
8,000,000
-4,747,628
12,747,628
-34,580,912
-3,203,663
-176,125
-859,332
38,820,032
Hire Purchase and Lease Commitments
-1,471,867
1,537,591
-542,233
-277,543
2,737,967
other long term liabilities
share issue
15,920,894
5,202
4,535,409
interest
-214,466
-298,389
-199,452
-200,000
-714,210
-824,349
3,017,255
-179,302
-231,210
-917
cash flow from financing
-2,235,966
30,365,494
1,004,173
-2,071,329
15,490,797
-35,391,649
-4,019,547
2,806,852
-816,715
38,720,453
-231,210
4,534,492
cash and cash equivalents
cash
5,861,389
2,250,769
1,115,499
768,934
-555,983
522,508
-213,427
-45,627
885,810
-935,719
59,876
-784,401
1,135,801
-574,105
1,754,616
overdraft
change in cash
5,861,389
2,250,769
1,115,499
768,934
-555,983
522,508
-213,427
-45,627
885,810
-935,719
59,876
-784,401
1,135,801
-574,105
1,754,616
vifor pharma uk limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for vifor pharma uk limited. Get real-time insights into vifor pharma uk limited's credit score, group structure and payment trends.
Perform a competitor analysis for vifor pharma uk limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in EC4A area or any other competitors across 12 key performance metrics.
The sole shareholder of Vifor Pharma Uk Limited is Vifor Pharma Participations Ag.
vifor pharma participations ag
100%
vifor pharma uk limited directors
Vifor Pharma Uk Limited currently has 2 directors.
The longest serving directors include
Mr Alexandros Sigalas (Sep 2010) and
Mr Stephen Allan (Apr 2024).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to vifor pharma uk limited. Currently there are 1 open charges and 0 have been satisfied in the past.
vifor pharma uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VIFOR PHARMA UK LIMITED. This can take several minutes, an email will notify you when this has completed.
vifor pharma uk limitedCompanies House Filings - See Documents
